NCT06807294 Feasibility Testing of a Tai Chi Program for Chemotherapy-Induced Peripheral Neuropathy Treatment (TCT)
| NCT ID | NCT06807294 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dana-Farber Cancer Institute |
| Condition | Chemotherapy Induced Peripheral Neuropathy (CIPN) |
| Study Type | INTERVENTIONAL |
| Enrollment | 21 participants |
| Start Date | 2026-01-16 |
| Primary Completion | 2026-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 21 participants in total. It began in 2026-01-16 with a primary completion date of 2026-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This research is being done to determine whether a 12-week virtual Tai Chi training program, designed to improve balance and small nerve fiber function, is feasible and acceptable among cancer survivors with chemotherapy-induced peripheral neuropathy (CIPN).
Eligibility Criteria
Inclusion Criteria: * Age 18 years old and older * Cancer survivors with no evidence of disease (cancer); * Completed neurotoxic chemotherapy, i.e., platinum agents, taxanes, vinca alkaloids, and bortezomib, at least three months before enrollment; * A CIPN diagnosis based on symptom history, loss of deep tendon reflexes, or presence of symmetrical stocking-glove pain, numbness, or paresthesia; * Answers "yes" to the following question: "Do you feel as though your balance is affected from experiencing CIPN?" or "Are you afraid of falling as a result of your CIPN?"; * On a stable regimen (no change in past three months) if taking anti-neuropathy or other pain medications; * Eastern Cooperative Oncology Group (ECOG) Performance Status Scale score ≤ 2 * Willing to adhere to all study-related procedures, including randomization to the Tai Chi or waitlist group, 2 in-person visits to Dana-Farber Cancer Institute (DFCI) (one within 2 weeks of enrollment and one at week 12); * Willing to adhere to requirement that no new pain medication be taken throughout the study period; and * Individuals receiving endocrine therapy or targeted/antibody therapy, such as trastuzumab, pertuzumab, or immunotherapy, will be eligible to participate. Exclusion Criteria: • Patients who have received physical therapy or Tai Chi training, specifically for CIPN, in the past three months.
Contact & Investigator
Ting Bao, MD
PRINCIPAL INVESTIGATOR
Dana-Farber Cancer Institute
Frequently Asked Questions
Who can join the NCT06807294 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chemotherapy Induced Peripheral Neuropathy (CIPN). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06807294 currently recruiting?
Yes, NCT06807294 is actively recruiting participants. Contact the research team at ting_bao@dfci.harvard.edu for enrollment information.
Where is the NCT06807294 trial being conducted?
This trial is being conducted at Boston, United States.
Who is sponsoring the NCT06807294 clinical trial?
NCT06807294 is sponsored by Dana-Farber Cancer Institute. The principal investigator is Ting Bao, MD at Dana-Farber Cancer Institute. The trial plans to enroll 21 participants.